# A Post-Marketing Observational Study of VYXEOS™

> **NCT03526926** · — · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Therapy-Related Acute Myeloid Leukemia

## Interventions

- **DRUG:** CPX-351

## Key facts

- **NCT ID:** NCT03526926
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-23
- **Primary completion:** 2019-10-26
- **Final completion:** 2020-06-12
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2020-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526926, "A Post-Marketing Observational Study of VYXEOS™". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03526926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*